8-K: DBV Technologies Completes Screening for VITESSE Phase 3 Clinical Trial Ahead of Schedule

DBV Technologies has successfully completed patient screening for its VITESSE Phase 3 trial of the Viaskin Peanut Patch, evaluating its efficacy in peanut-allergic children aged 4-7 years.

Summary

• DBV Technologies has completed screening for the VITESSE Phase 3 clinical trial, which is evaluating the Viaskin Peanut Patch in children aged 4 to 7 with peanut allergies.
• The company exceeded its recruitment goals for the trial in Q3 2024.
• The screening process was completed in August, a month earlier than anticipated.
• The VITESSE trial is the largest immunotherapy clinical trial for this patient population, with over 600 subjects enrolled across 86 sites in multiple countries.
• Topline results from the VITESSE trial are expected by Q4 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of screening ahead of schedule and the large scale of the trial. The company is progressing well with its clinical program.

Positives

• The company exceeded its recruitment goals for the VITESSE trial.
• Screening was completed a month earlier than expected.
• The trial has a diverse patient population.
• The VITESSE trial is the largest treatment intervention study in peanut allergy.

Risks

• The forward-looking statements are subject to risks and uncertainties related to research and development, clinical trials, regulatory reviews, and the company's ability to execute its budget.
• The product candidates have not been authorized for sale in any country.

Future Outlook

DBV Technologies is focused on advancing the Viaskin Peanut program to support a Biologic License Application submission and anticipates topline results from the VITESSE trial by Q4 2025.

Management Comments

• Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies, stated that they are thrilled to have reached this significant milestone.
• Dr. Mohideen also expressed gratitude to the study centers, subjects, and their families for their dedication and commitment.

Industry Context

This announcement is significant in the context of the growing need for effective treatments for food allergies, particularly in children. The completion of screening for the VITESSE trial represents a major step forward in DBV Technologies' efforts to address this unmet medical need.

Comparison to Industry Standards

• The VITESSE trial is described as the largest immunotherapy clinical trial for peanut allergies in children aged 4-7, indicating a significant scale compared to other studies in the field.
• Other companies such as Aimmune Therapeutics (now part of Nestle Health Science) have developed oral immunotherapy treatments for peanut allergies, but DBV's approach using the Viaskin patch is a different method of delivery.
• The trial's size and global reach across 86 sites in multiple countries suggests a comprehensive approach to evaluating the Viaskin Peanut Patch.

Stakeholder Impact

• The successful completion of screening is positive for shareholders, as it indicates progress in the company's clinical program.
• The trial's progress is also positive for patients and their families who are seeking new treatment options for peanut allergies.
• The study centers involved in the trial are also key stakeholders.

Next Steps

• DBV Technologies will continue to advance the Viaskin Peanut program.
• The company will work towards a Biologic License Application submission.
• Topline results from the VITESSE trial are expected by Q4 2025.

Key Dates

Keywords

Viaskin Peanut Patch, Peanut Allergy, Clinical Trial, Immunotherapy, VITESSE, DBV Technologies, EPIT, Food Allergy